Carvedilol phosphate hemihydrate

首页蛋白库基因库产品会员服务

位置：首页 > 产品库 > Carvedilol phosphate hemihydrate

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

610309-89-2

包装与价格：

包装	价格(元)
100mg	询价
500mg	询价

Carvedilol (phosphate hemihydrate) (BM 14190 (phosphate hemihydrate)) 是非选择性 β 和 α1 阻断剂, 能抑制 LDL 的氧化, IC50为 3.8 μM。

Cas No.	610309-89-2
别名	卡维地洛磷酸盐,BM 14190 phosphate hemihydrate
Canonical SMILES	O=P(OO)=O.OC(CNCCOC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4.[HH].[0.5H2O]
分子式	C₂₄H₂₆N₂O₄. H₃PO₄.₁/₂H₂O
分子量	513.48
溶解度	Soluble in DMSO
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	Carvedilol (phosphate hemihydrate) (BM 14190 (phosphate hemihydrate)) is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation. IC50: 3.8 μM (beta Adrenergic Receptor). Carvedilol (BM 14190) is a nonselective-blocking agent and is used in the treatment of hypertension and angina pectoris. As a third-generation β-adrenergic blocker (β-blocker), Carvedilol is able to reverse cardiac structural remodeling. Recentresults demonstrated that the effect caused by Carvedilol on cardiac remodeling is largely dependent on endogenous NO. [1]. Chen J, et al. The effects of carvedilol on cardiac structural remodeling: The role of endogenous nitric oxide in the activity of carvedilol. Mol Med Rep. 2013 Apr;7(4):1155-1158. [2]. Stafylas PC, et al. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30. [3]. Othman AA, et al. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007 Jun 15;9(2):E208-18. [4]. Koshimizu TA, et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-672.